Biologic medicines have transformed treatment for numerous chronic and life-threatening conditions such as cancer, ...
The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...
Market OverviewThe Global Breast Cancer Therapeutics Market remains one of the most prevalent forms of cancer worldwide, ...
The success of NIPRO’s biosimilar product, launched in late 2023, has exceeded expectations and gained significant market ...
GlobalData on MSN3d
Bio-Thera signs US deal with Intas for golimumab biosimilarBio-Thera Solutions has signed an exclusive licence and commercialisation agreement with Intas Pharmaceuticals for BAT2506 in ...
After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...
Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative ...
Newsweek on MSN11d
Cancer's Hidden Cost Burden Strains Patients and Health Systems: ReportThe cost of cancer may be higher than previously estimated, according to a recent report from the American Cancer Society.
Biocon plans to list its biosimilars business by March 2026, targeting a double-digit market share in the U.S. with five new ...
The company, which has been pushing its IPO plans for the past year, has been waiting to complete the integration of its acquired biosimilars firm Viatris and refinance debt before it goes public ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback